Inhibition of GSK3B Bypass Drug Resistance of p53-Null Colon Carcinomas by Enabling Necroptosis in Response to Chemotherapy

Purpose: Evasion from chemotherapy-induced apoptosis due to p53 loss strongly contributes to drug resistance. Identification of specific targets for the treatment of drug-resistant p53-null tumors would therefore increase the effectiveness of cancer therapy. Experimental Design: By using a kinase-directed short hairpin RNA library and HCT116p53KO drug-resistant colon carcinoma cells, glycogen synthase kinase 3 beta (GSK3B) was identified as a target whose silencing bypasses drug resistance due to loss of p53. p53-null colon cancer cell lines with different sets of mutations were used to validate the role of GSK3B in sustaining resistance and to characterize cell death mechanisms triggered by chemotherapy when GSK3B is silenced. In vivo xenograft studies were conducted to confirm resensitization of drug-resistant cells to chemotherapy upon GSK3 inhibition. Colon cancer samples from a cohort of 50 chemotherapy-treated stage II patients were analyzed for active GSK3B expression. Results: Downregulation of GSK3B in various drug-resistant p53-null colon cancer cell lines abolished cell viability and colony growth after drug addition without affecting cell proliferation or cell cycle in untreated cells. Cell death of 5-fluorouracil (5FU)–treated p53-null GSK3B-silenced colon carcinoma cells occurred via PARP1-dependent and AIF-mediated but RIP1-independent necroptosis. In vivo studies showed that drug-resistant xenograft tumor mass was significantly reduced only when 5FU was given after GSK3B inhibition. Tissue microarray analysis of colon carcinoma samples from 5FU-treated patients revealed that GSK3B is significantly more activated in drug-resistant versus responsive patients. Conclusions: Targeting GSK3B, in combination with chemotherapy, may represent a novel strategy for the treatment of chemotherapy-resistant tumors. Clin Cancer Res; 19(14); 3820–31. ©2013 AACR.

[1]  P. Lan,et al.  [Adjuvant chemotherapy for stage II colon cancer]. , 2012, Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery.

[2]  W. Kraus,et al.  On PAR with PARP: cellular stress signaling through poly(ADP-ribose) and PARP-1. , 2012, Genes & development.

[3]  D. Kozono,et al.  Necroptosis is a novel mechanism of radiation-induced cell death in anaplastic thyroid and adrenocortical cancers. , 2011, Surgery.

[4]  Rebecca SY Wong,et al.  Apoptosis in cancer: from pathogenesis to treatment , 2011, Journal of experimental & clinical cancer research : CR.

[5]  Zsuzsanna A. Dunai,et al.  Necroptosis: Biochemical, Physiological and Pathological Aspects , 2011, Pathology & Oncology Research.

[6]  A. Gross,et al.  BID regulates AIF-mediated caspase-independent necroptosis by promoting BAX activation , 2011, Cell Death and Differentiation.

[7]  M. Bissonnette,et al.  Upregulation of glycogen synthase kinase 3β in human colorectal adenocarcinomas correlates with accumulation of CTNNB1. , 2011, Clinical colorectal cancer.

[8]  T. Hunter,et al.  Protein kinase signaling networks in cancer. , 2011, Current opinion in genetics & development.

[9]  R. King,et al.  Vigilance and validation: Keys to success in RNAi screening. , 2011, ACS chemical biology.

[10]  A. Palazzo,et al.  Past, present and future of targeted therapy in solid tumors. , 2010, Current cancer drug targets.

[11]  Russ B Altman,et al.  PharmGKB summary: fluoropyrimidine pathways. , 2010, Pharmacogenetics and genomics.

[12]  G. Oakley,et al.  Replication protein A: directing traffic at the intersection of replication and repair. , 2010, Frontiers in bioscience.

[13]  T. Vanden Berghe,et al.  The Role of the Kinases RIP1 and RIP3 in TNF-Induced Necrosis , 2010, Science Signaling.

[14]  G. Biasi,et al.  Pathogenetic role of hypercholesterolemia in a novel preclinical model of vascular injury in pigs. , 2009, Atherosclerosis.

[15]  K. Kawakami,et al.  Deregulated GSK3 Sustains Gastrointestinal Cancer Cells Survival by Modulating Human Telomerase Reverse Transcriptase and Telomerase , 2009, Clinical Cancer Research.

[16]  Z. Wainberg,et al.  Adjuvant Chemotherapy for Stage II Colon Cancer: The Role of Molecular Markers in Choosing Therapy. , 2009, Gastrointestinal cancer research : GCR.

[17]  B. Wouters,et al.  Hypoxia signalling through mTOR and the unfolded protein response in cancer , 2008, Nature Reviews Cancer.

[18]  Mark J. Murphy,et al.  Glycogen synthase kinase 3 in MLL leukaemia maintenance and targeted therapy , 2008, Nature.

[19]  A. Baldwin,et al.  Maintenance of constitutive IkappaB kinase activity by glycogen synthase kinase-3alpha/beta in pancreatic cancer. , 2008, Cancer research.

[20]  Alexei Degterev,et al.  Identification of RIP1 kinase as a specific cellular target of necrostatins. , 2008, Nature chemical biology.

[21]  N. Kay,et al.  Inhibition of glycogen synthase kinase-3 activity leads to epigenetic silencing of nuclear factor kappaB target genes and induction of apoptosis in chronic lymphocytic leukemia B cells. , 2007, Blood.

[22]  T. Dale,et al.  Glycogen synthase kinase 3: A key regulator of cellular fate , 2007, Cellular and Molecular Life Sciences.

[23]  Jianhong Luo,et al.  Shikonin circumvents cancer drug resistance by induction of a necroptotic death , 2007, Molecular Cancer Therapeutics.

[24]  Herb Chen,et al.  Inactivation of glycogen synthase kinase-3β, a downstream target of the raf-1 pathway, is associated with growth suppression in medullary thyroid cancer cells , 2007, Molecular Cancer Therapeutics.

[25]  G. Wahl,et al.  Regulating the p53 pathway: in vitro hypotheses, in vivo veritas , 2006, Nature Reviews Cancer.

[26]  S. Fulda,et al.  Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy , 2006, Oncogene.

[27]  R. Jope,et al.  The paradoxical pro- and anti-apoptotic actions of GSK3 in the intrinsic and extrinsic apoptosis signaling pathways , 2006, Progress in Neurobiology.

[28]  L. Wiesmüller,et al.  p53 in recombination and repair , 2006, Cell Death and Differentiation.

[29]  T. Anthony,et al.  Coping with stress: eIF2 kinases and translational control. , 2006, Biochemical Society transactions.

[30]  E. Liu,et al.  Pharmacologic modulation of glycogen synthase kinase-3beta promotes p53-dependent apoptosis through a direct Bax-mediated mitochondrial pathway in colorectal cancer cells. , 2005, Cancer research.

[31]  Bin Zhang,et al.  Deregulated GSK3beta activity in colorectal cancer: its association with tumor cell survival and proliferation. , 2005, Biochemical and biophysical research communications.

[32]  M. Ozturk,et al.  Lithium‐mediated downregulation of PKB/Akt and cyclin E with growth inhibition in hepatocellular carcinoma cells , 2005, International journal of cancer.

[33]  J. C. Ghosh,et al.  Activation of p53-Dependent Apoptosis by Acute Ablation of Glycogen Synthase Kinase-3β in Colorectal Cancer Cells , 2005, Clinical Cancer Research.

[34]  G. Giaccone,et al.  Cell Death Independent of Caspases: A Review , 2005, Clinical Cancer Research.

[35]  R. Urrutia,et al.  Glycogen Synthase Kinase-3β Participates in Nuclear Factor κB–Mediated Gene Transcription and Cell Survival in Pancreatic Cancer Cells , 2005 .

[36]  D. Villa,et al.  Resveratrol interference with the cell cycle protects human neuroblastoma SH-SY5Y cell from paclitaxel-induced apoptosis , 2005, Neurochemistry International.

[37]  M. Mareel,et al.  The proinvasive activity of Wnt‐2 is mediated through a noncanonical Wnt pathway coupled to GSK‐3β and c‐ Jun/AP‐1 signaling , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[38]  J. Waxman,et al.  Inhibition of glycogen synthase kinase-3 represses androgen receptor activity and prostate cancer cell growth , 2004, Oncogene.

[39]  M. Somerfield,et al.  American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  K. Helin,et al.  Loss of MYC Confers Resistance to Doxorubicin-induced Apoptosis by Preventing the Activation of Multiple Serine Protease- and Caspase-mediated Pathways* , 2004, Journal of Biological Chemistry.

[41]  T. Dawson,et al.  Nuclear and mitochondrial conversations in cell death: PARP-1 and AIF signaling. , 2004, Trends in pharmacological sciences.

[42]  Reuven Agami,et al.  A large-scale RNAi screen in human cells identifies new components of the p53 pathway , 2004, Nature.

[43]  Magali Olivier,et al.  The Tumor Suppressor Gene TP53: Implications for Cancer Management and Therapy , 2004, Critical reviews in clinical laboratory sciences.

[44]  J. Thrasher,et al.  Glycogen synthase kinase-3beta suppression eliminates tumor necrosis factor-related apoptosis-inducing ligand resistance in prostate cancer. , 2003, Molecular cancer therapeutics.

[45]  T. Illidge,et al.  Endopolyploid cells produced after severe genotoxic damage have the potential to repair DNA double strand breaks , 2003, Journal of Cell Science.

[46]  K. Kinzler,et al.  Disruption of p53 in human cancer cells alters the responses to therapeutic agents. , 1999, The Journal of clinical investigation.

[47]  Hans Clevers,et al.  Activation of β-Catenin-Tcf Signaling in Colon Cancer by Mutations in β-Catenin or APC , 1997, Science.

[48]  Michael Hummel,et al.  Supplementary Figure 3 , 2010 .

[49]  P. Muti,et al.  RIPK1/RIPK3 promotes vascular permeability to allow tumor cell extravasation independent of its necroptotic function , 2017, Cell Death & Disease.

[50]  Valeria Panebianco,et al.  Supplementary Figure 2 , 2012 .

[51]  E. Henske,et al.  Supplementary Figure 6 , 2011 .

[52]  H. Urlaub,et al.  Supplementary Table 3 , 2011 .